Michael has been an Associate Director with Pfizer's Veterinary Medicine Research and Development Division since March 2005. He is responsible for the EU clinical development programme for Improvac including the design, conduct, and reporting of clinical safety and efficacy studies to support product registration, an extensive programme of field trials across Europe, and several collaborative research projects.
During his Fellowship assignment with GALVMed, Michael will train and mentor Onderstepoort Veterinary Institute (OVI) staff to run clinical trials to VICH standards providing material suitable for inclusion in safety and efficacy components of vaccine registration dossiers. Michael will also provide data management and epidemiological expertise to support clinical trials.
From his Fellowship experience, Michael will learn more about infectious animal diseases of major importance to the African livestock industry such as Rift Valley fever. Michael believes he shall return from his assignment with enhanced leadership skills and a greater understanding of issues concerning the development and provision of high quality vaccines for the control of infectious animal diseases in Africa.
GALVmed is a not-for-profit global alliance of public, private and government partners, protecting livestock and saving human life by making livestock vaccines, diagnostics and medicines accessible and affordable to the millions for whom livestock is a lifeline. With offices in the United Kingdom and Africa, GALVmed is funded by the Bill & Melinda Gates Foundation and the Department for International Development.